PARP1 inhibition by Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcitabine.

Artículo original

Año: 2022

Quinonero, F; Mesas, C; Munoz-Gamez, JA; Jimenez-Luna, C; Perazzoli, G; Prados, J; Melguizo, C; Ortiz, R

Título: BIOMEDICINE & PHARMACOTHERAPY

• D1